Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Drug Profile

Phosphorylcholine monoclonal antibody - Athera Biotechnologies

Alternative Names: 3G10; Fully human monoclonal IgG phosphorylcholine antibody - Athera Biotechnologies; IgG phosphorylcholine antibody; PC-mAb; PCmab; Phosphorylcholine monoclonal antibody - Athera

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dyax
  • Developer Athera Biotechnologies
  • Class Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action LDL receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atherosclerosis
  • Phase I Cardiovascular disorders
  • Clinical Phase Unknown Peripheral arterial disorders
  • Preclinical Coronary artery restenosis

Most Recent Events

  • 06 Sep 2017 Phase-II clinical trials in Atherosclerosis in Sweden, Netherlands (IV) (EudraCT2017-002106-13)
  • 30 Aug 2017 Athera Biotechnologies plans a phase IIa study of phosphorylcholine monoclonal antibody for Peripheral arterial disorders in 2017
  • 28 Aug 2017 Phosphorylcholine monoclonal antibody - Athera Biotechnologies receives Orphan Drug status for Renal failure (End stage renal disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top